Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin7.2%+2.2pp5%
Operating margin-881.3%-13.5pp-867.9%+788pp-1,656.2%-650pp-1,005.8%-45.7pp-960.1%-146pp
Net margin-842.9%+20.4pp-863.4%+774pp-1,637.8%-633pp-1,004.9%-43.6pp-961.3%-173pp
Returns
Return on equity-57.2%+2.4pp-59.5%+31.5pp-91.1%-4.7pp-86.3%-0.2pp-86.1%-24.2pp
Return on invested capital-118.2%+6.4pp-124.6%+85.2pp-209.8%-28.7pp-181.1%-14.3pp-166.8%-25.8pp
Efficiency
Asset turnover0.1×0.0×0.1×0.0×0.0×0.1×0.0×0.1×0.0×
Liquidity
Current ratio5.5×0.0×5.5×+0.9×4.6×+1.0×3.6×-0.5×4.1×+0.3×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$1.94-23.4%$2.53+7.9%$2.34+6.4%$2.20-5.0%$2.32-38.6%
Valuation
Market capitalization$1.62B-23.8%$2.13B-0.1%$2.13B+0.4%$2.12B-0.2%$2.13B-19.5%
Price / sales24.4×-4.1×28.5×-20.3×48.8×+15.9×32.8×-2.7×35.6×-9.3×
Price / book1.6×-0.3×1.9×-0.2×-0.3×2.3×0.0×2.3×-0.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Recursion Pharmaceuticals, Inc.'s profit margins?
Recursion Pharmaceuticals, Inc. (RXRX) runs a 7.2% gross margin and a -881.3% operating margin, with a -842.9% net margin.
Where do Recursion Pharmaceuticals, Inc.'s ratios come from?
Every ratio is computed from Recursion Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.